首页> 外文OA文献 >An Asian Regional Analysis of Cost-Effectiveness of Early Irbesartan Treatment versus Conventional Antihypertensive, Late Amlodipine, and Late Irbesartan Treatments in Patients with Type 2 Diabetes, Hypertension, and Nephropathy

【2h】

An Asian Regional Analysis of Cost-Effectiveness of Early Irbesartan Treatment versus Conventional Antihypertensive, Late Amlodipine, and Late Irbesartan Treatments in Patients with Type 2 Diabetes, Hypertension, and Nephropathy

机译：亚洲地区早期2型糖尿病，高血压和肾病患者厄贝沙坦治疗与常规降压，氨氯地平晚期和厄贝沙坦治疗的成本-效果分析

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
Annemans Lieven; Demarteau Nadia; Hu Shanlian; Lee Tae-Jin; Morad Zaher; Supaporn Thanom; Yang Wu-Chang; Palmer Andrew J.;
展开▼
作者单位

展开▼
年度 2008
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. An Asian regional analysis of cost-effectiveness of early irbesartan treatment versus conventional antihypertensive, late amlodipine, and late irbesartan treatments in patients with type 2 diabetes, hypertension, and nephropathy. [J] . Annemans L, Demarteau N, Hu S, Value in health: the journal of the International Society for Pharmacoeconomics and Outcomes Research . 2008,第3期

机译：亚洲地区对2型糖尿病，高血压和肾病患者早期厄贝沙坦治疗与常规降压，氨氯地平晚期和厄贝沙坦晚期治疗的成本-效果分析。
2. An economic evaluation of irbesartan in the treatment of patients with type 2 diabetes, hypertension and nephropathy: cost-effectiveness of Irbesartan in Diabetic Nephropathy Trial (IDNT) in the Belgian and French settings. [J] . Palmer AJ, Annemans L, Roze S, Nephrology, dialysis, transplantation: official publication of the European Dialysis and Transplant Association - European Renal Association . 2003,第10期

机译：厄贝沙坦治疗2型糖尿病，高血压和肾病患者的经济评价：在比利时和法国的糖尿病肾病试验（IDNT）中，厄贝沙坦的成本效益。
3. Cost-Effectiveness of Early Irbesartan Treatment Versus Control (Standard Antihypertensive Medications Excluding ACE Inhibitors, Other Angiotensin-2 Receptor Antagonists, and Dihydropyridine Calcium Channel Blockers) or Late Irbesartan Treatment in P [J] . Palmer AJ, Annemans L, Roze S, Diabetes care . 2004,第8期

机译：早期厄贝沙坦治疗与对照（标准降压药物（不包括ACE抑制剂，其他血管紧张素2受体拮抗剂和二氢吡啶类钙通道阻滞剂）和P型厄贝沙坦治疗）的成本效果
4. Use of ~(99m)Tc-HMPAO in Estimating the Antihypertensive Therapy Impact on the Cerebral Perfusion in Patients with Arterial Hypertension Associated with Diabetes Mellitus Type 2 [C] . EFIMOVA Irina Yu, BELOKOPYTOVA Nataliya V., EFIMOVA Nataliya Yu, International Conference on Physical-Technical Problems of Nuclear Science, Energy Generation and Power Industry . 2015

机译：使用〜（99米）TC-HMPAO在患有糖尿病患者患者患者患者脑灌注的抗高血压治疗对糖尿病2型型2时的影响
5. Pharmacoeconomic analysis of antihypertensive treatment in a population with type 2 diabetes. [D] . Patel, Rajul Arvind. 2007

机译：2型糖尿病人群抗高血压治疗的药物经济学分析。
6. Cost-effectiveness of Chlorthalidone Amlodipine and Lisinopril as First-step Treatment for Patients with Hypertension: An Analysis of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) [O] . Paul A. Heidenreich, Barry R. Davis, Jeffrey A. Cutler, 2008

机译：氯噻酮氨氯地平和赖诺普利作为高血压患者的第一步治疗的成本效益：降压降脂治疗预防心脏病发作试验的分析（ALLHAT）
7. Cost-effectiveness of early irbesartan treatment versus control (standard antihypertension medications excluding ACE inhibitors, other angiotensin-2 receptor antagonists, and dihydropyridine calcium channel blockers) or late irbesartan treatment in patients with type 2 diabetes, hypertension, and renal disease [O] . Palmer, A.J., Annemans, L., Roze, S., 2004

机译：早期厄贝沙坦治疗与对照（标准抗高血压药物不包括ACE抑制剂，其他血管紧张素2受体拮抗剂和二氢吡啶类钙通道阻滞剂）或晚期厄贝沙坦治疗在2型糖尿病，高血压和肾病患者中的成本效益

An Asian Regional Analysis of Cost-Effectiveness of Early Irbesartan Treatment versus Conventional Antihypertensive, Late Amlodipine, and Late Irbesartan Treatments in Patients with Type 2 Diabetes, Hypertension, and Nephropathy

著录项

相似文献

相关主题

期刊订阅